ACOR


J.P. Morgan Cuts Price Target on Acorda (ACOR) Stock Following Negative Ruling on Ampyra Patent

Did an iceberg just wallop into Acorda (ACOR) stock? The drug maker’s shares are plunging at breakneck speed of almost 22% after the U.

Acorda Therapeutics Inc (ACOR) and Finish Line Inc (FINL) Fell Off a Cliff; Analysts Look for Survivors

Can These Biotech Stocks Recover from an FDA Setback and a Stark 2Q Preliminary Earnings Stumble?

Acorda Therapeutics Inc (ACOR) Shares Are Getting Hammered; Here’s Why

Acorda Therapeutics Inc (NASDAQ:ACOR) stock got hammered 26% Tuesday morning as Wall Street came down hard on the company. The reason?

Acorda Therapeutics Inc (ACOR): Key Takeaways from CVT-301 Presentation at MDS

Yesterday afternoon, Acorda Therapeutics Inc (NASDAQ:ACOR) presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically …

Acorda Therapeutics Inc (ACOR) Is Undervalued for CVT-301’s Potential: Cowen

Acorda Therapeutics Inc (NASDAQ:ACOR) shares climbed nearly 10% to $16.80 in after-hours trading Monday, after the drug maker announced that its Parkinson’s disease drug, …

Acorda Therapeutics Inc (ACOR) Faces Clear Setback With Unfavorable Ampyra Ruling

On Friday, Acorda Therapeutics Inc (NASDAQ:ACOR) was met with misfortune after a district judge invalidated four patents for its multiple sclerosis drug Ampyra, …

Friday’s Market Insights: Akari Therapeutics PLC (ADR) (AKTX), Acorda Therapeutics Inc (ACOR), BlackBerry Ltd (BBRY)

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares skyrocketed over 40% in Friday’s trading session, after the company announced that the FDA has designated as …

J.P. Morgan Provides Thoughts On Acorda Therapeutics Inc (ACOR)

Acorda Therapeutics Inc (NASDAQ:ACOR) shares rose 13% in Thursday’s trading session, after the drug maker announced topline data for CVT-301, an inhaled levodopa therapy …

Stock Update (NASDAQ:ACOR): Here’s Why Acorda Therapeutics Inc Shares Are Falling 10% Today

Acorda Therapeutics Inc (NASDAQ:ACOR) investors are having a rough morning, after the drug maker announced that it plans to discontinue the development of Ampyra …